Atrial fibrillation during adjuvant chemotherapy with docetaxel: A case report

Tumori

Volumn 88, Issue 6, 2002, Pages 527-529

  Palma, Marzia ^a   Mancuso, Andrea ^a   Grifalchi, Federico ^a   Lugini, Antonio ^a   Pizzardi, Nicoletta ^a   Cortesi, Enrico ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Atrial fibrillation; Breast cancer; Cardiac dysfunction

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIAZEPAM; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCERYL TRINITRATE; IFOSFAMIDE; MELPHALAN; ONDANSETRON; PACLITAXEL; PROPAFENONE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CASE REPORT; CONGESTIVE HEART FAILURE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; THYROID DISEASE;

EID: 0036880382     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160208800618     Document Type: Article

References (36)

1. Hudis C: Chemotherapy for early-stage breast cancer. Am Soc Clin Oncol Educational Book: 266-273, 2000.
2. Viens P, Kerbrat P, Fumoleau P, Guastalla JP, Roche H, Delozier T, Marcillac I, Bardonnet M: Epirubicin in combination with docetaxel as first-line chemotherapy of metastatic breast cancer: preliminary results of phase I dose finding study. Proc ASCO, 16: 690A, 1997.
3. Rosso R, Palmieri S, Tamburo De Bella M, Gridelli C: Meccanismo d'azione; farmacocinetica e metabolismo; studi di fase I. In: Docetaxel: farmacologia e clinica, Rosso R (ed), pp 3-8, 69-74, 91-101, Mosby Italia, Milano, 1998.
4. Cazap E, Ventriglia E, Rubio G, Estevez R: Taxol plus doxorubicin in the treatment of metastatic breast cancer ambulatory patients. Proc ASCO, 15: 248A, 1996.
5. Dombernowsky, P, Gehl J, Boesgaard M, Paaske T, Jensen BV: Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol, 23 (suppl 11): 23-27, 1996.
6. Frassineti GL, Zoli W, Silvestro L, Serra P, Milandri C, Tienghi A, Gianni L, Gentile A, Salzano E, Amadori D: Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol, 24 (suppl 17): S17-25, 1997.
7. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol, 7: 687-693, 1996.
8. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol, 13: 2688-2699, 1995.
9. Gianni L, Capri G, Tarenzi E, Fulfaro F, Villani F, Valagussa P, Bonadonna G: Efficacy and cardiac effects of 3-hour paclitaxel plus bolus doxorubicin in women with untreated metastatic breast carcinoma. Proc ASCO, 15: 128A, 1996.
10. Sledge GW Jr, Neuberg D, Ingle J, Wood W: Phase III trial of doxorubicin versus paclitaxel as first-line therapy for metastatic breast cancer: an intergroup trial. Proc ASCO, 16: 2A, 1997.
11. Schwartsmann G, Menke CH, Caleffi M, Xavier N, Ferreira Filho AF, Schunemann H, Koya R, Stroda PR, Pohlmann P, Venegas LF, Kalakun L: Phase II trail of taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Proc ASCO, 15: 168A, 1996.
12. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC: Phase II trial of doxorubicin plus paclitaxel plus G-CSF in metastatic breast cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol, 17: 3828-3834, 1999.
13. Sparano JA, Speyer J, Gradishar W: Phase I trial of zinecard, adriamycin, and escalating doses of taxol in advanced breast cancer (T95-0054). Breast Cancer Res Treat, 46: 56, 1997.
14. Aapro MS: Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin Oncol, 26 (suppl 3): 17-21, 1999.
15. Dieras V: Docetaxel in combination with doxorubicin: a phase I dose-finding study. Oncology, 11 (suppl 6): 7-20, 1997.
16. Dieras V: Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer. Semin Oncol, 25 (suppl 12): 18-22, 1998.
17. Dieras V, Barthier S, Beuzeboc P: Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat, 50: 262, 1998.
18. Itoh K, Fujii H, Minami H, Ohtsu T, Wakita H, Igarashi T, Sasaki Y, Kashimura M: Phase I and pharmacological study of docetaxel combined with doxorubicin for advanced breast cancer. Proc ASCO, 16: 610A, 1997.
19. Kennedy MJ, Elza K, Donehower R: Phase I and pharmacologic study of docetaxel and doxorubicin in patients with solid tumors: dose limiting toxicity at the first dose level. Proc ASCO, 16: 845A, 1997.
20. Misset JL, Dieras V, Bozec, Boutgeois H, Gruia G, Kalla S, Giacchetti S, Cvitkovic E, Aussel J, Azli N, Riva A, Pouillart P: Long term follow up of the phase I/II study of docetaxel and doxorubicin as 1st line chemotherapy of metastatic breast cancer. Proc ASCO, 17: 613A, 1998.
21. Nabholtz JM, Smylie M, Mackey JR, Noel D, Paterson AH, al-Tweigeri T, Au D, Sansregret E, Delorme F, Riva A: Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology, 11 (suppl 8): 37-41, 1997.
22. Nabholtz JM, Mackey JR, Smylie M, Paterson A, Noel D, al-Tweigeri T, Delorme F, Riva A: Phase II study of taxotere (docetaxel), doxorubicin and cyclophosphamide (TAC) in the treatment of metastatic breast cancer. Proc ASCO, 16: 518A, 1997.
23. Nabholtz JM, Mackey JR, Smylie M: Final results of a phase II study of docetaxel, doxorubicin and cyclophosphamide (TAC) as first-line chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat, 50: 27, 1998.
24. Nabholtz JM, Falkson G, Campos, Szanto J, Martin M, Chan S, Pienkowki T, Bezwoda WR, Zahiski J, Pinter T, Krzakowski M, Vorobief D, Leonard R, Kennedy I, Azli N, Murawski M, Riva A, Pouillort P, on behalf of the International TAX 306 Study Group: A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proc ASCO, 18: 127, 485A, 1999.
25. Nabholtz JM, Smylie M, Mackey J, Au HJ, Tonkin K, Morrish D, Salter E: Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer. Semin Oncol, 26 (suppl 8): 47-52, 1999.
26. Nabholtz JM, North S, Smylie M, Mackey J, Au HJ, Au R, Morris D, Salter E, Tonkin K: Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer. Semin Oncol: 27 (suppl 3): 11-18, 2000.
27. Pagani O: Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer. Semin Oncol, 25 (suppl 12): 23-26, 1998.
28. Sparano JA, Smylie M, Mackey J, Paterson A, Noel D, al-Tweigeri T, Janowska A, Delorme F, Riva A: Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer. Oncology, 11 (suppl 6): 25-27, 1997.
29. Sparano JA, Ju P, Scheafer PL: Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study (E1196). Breast Cancer Res Treat, 50: 27, 1998.
30. Sparano JA: Doxorubicin/Taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol, 26 (suppl 9): 14-19, 1999.
31. D'Incalci M, Schüller J, Colombo T, Zucchetti M, Riva A: Taxoids in combination with antracyclines and other agents: pharmacokinetic considerations. Semin Oncol, 25 (suppl 13): 16-20, 1998.
32. Minotti G, Saponiero A, Licata S, Menna P, Calafiore AM, Teodori G, Gianni L: Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res, 7: 1511-1515, 2001.
33. Bissett D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res, 53: 523-527, 1993.
34. Crown JP, Donnellan P, Sullivan C, Rowan S, Jones M, Chan KM, Duffy K, O'Leary M, Breathnach O, Moulton BC, MacErlean D, Schrance M, Murray R, Nutty S, Flynn C, Fennelly D, Moriarty M, O'Neill S, Lynch V, Nicholas W, Gallagher C, Armstrong J: Phase I/II evaluation of escalating dose docetaxel, ifosfamide and cisplatin with lenograstim support, in patients with stage III/IV NSCLC: an Irish Clinical Oncology Research Group (ICORG). Proc ASCO, 18: 1840A, 1999.
35. Gob BC, Wang TL, Wong J, Lim HL, Lin J, Kong HL, Lee SC: Phase II trial of docetaxel (Taxotere) in inoperable stage III NSCLC. Proc ASCO, 16: 1686A, 1997.
36. Cresta S, Grasselli G, Martoni G, Lelli M, Manzutti M, Capri G, Buzzi F, Robustelli G, Frevola L, Mekhaldi S, Azli N, Gianni L: A randomized phase II study of alternating (AA) vs sequential (SS) vs the combination (CC) of doxorubicin (A) and docetaxel (T) as 1st line CT in MBC pts. Proc ASCO, 20: 190A, 2001.